Related Experiment Video
Updated: Oct 23, 2025
09:49
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
3.6K
Could erectile dysfunction be a side effect of CGRP inhibition? A case report
Linda Al-Hassany1, Tessa de Vries1, Johannes A Carpay2
1Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Cephalalgia : an International Journal of Headache
|August 18, 2021
Summary
New antimigraine drugs targeting calcitonin gene-related peptide (CGRP) may cause erectile dysfunction in men. This potential side effect appears reversible upon discontinuing CGRP inhibition therapy.
Area of Science:
- Neurology
- Pharmacology
Background:
- New preventive medications for migraine target the calcitonin gene-related peptide (CGRP) pathway.
- These CGRP inhibitors represent a novel therapeutic approach for migraine management.
Observation:
- A case study involving a 54-year-old male migraine patient reported erectile dysfunction.
- The erectile dysfunction was a potential side effect of galcanezumab, a CGRP-targeting monoclonal antibody.
- The patient's erectile function improved after discontinuing galcanezumab treatment.
Findings:
- Erectile dysfunction is a plausible side effect of CGRP inhibition due to CGRP's role in penile erection.
- The incidence and causal relationship between CGRP inhibition and erectile dysfunction require further investigation through postmarketing surveillance.
- This side effect is potentially reversible and may be overlooked in male migraine patients.
Implications:
- Clinical awareness of erectile dysfunction as a potential side effect of CGRP inhibitors is crucial.
- Further research is needed to confirm the link between CGRP inhibition and erectile dysfunction.
- Understanding this association is important due to the sexual and potential cardiovascular implications of erectile dysfunction, especially given its link to cardiovascular disease.
More Related Videos
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
282
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
282
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
517
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
517
01:09GPCRs Regulate Adenylyl Cylase Activity
6.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.2K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
37
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
37
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.1K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.1K
01:21Skeletal Muscle Relaxants: Adverse Effects
540
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
540